Janssen to sell Pfizer antidepressant in Korea; FDA flags off-label claims--for dogs;

> Johnson & Johnson's ($JNJ) Janssen will sell Pfizer's ($PFE) Effexor XR antidepressant in Korea. More

> Arena Pharmaceuticals' ($ARNA) Belviq marketing partner Eisai has upped its sales forces for the obesity drug once again to total about 600 reps. Release

> PharmaMar and Chugai Pharma Marketing have entered a licensing and commercialization agreement in Europe for multiple myeloma drug Aplidin. Release

> BIAL and specialty pharma moksha8 have announced an exclusive marketing deal for epilepsy treatment Zebinix/Exalief in Brazil and Mexico. Release

> Fendix Media has appointed Simon Grime as its new commercial director, putting him in charge of driving the growth of its network of websites for the U.K.'s NHS. Report

> Eli Lilly ($LLY) will sponsor this month's NASCAR Nationwide Series race as part of a multiyear deal. Report

> Purdue Pharma won FDA approval for a new 7.5-mcg/hour dosage of its Butrans Transdermal System. Release

And Finally... Even pharma marketing for dogs can run afoul of the FDA, according to an agency warning letter. More

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

Merck CEO Ken Frazier has spoken passionately about racism before. Monday, amid protests over George Floyd's death, he made that passion personal.

BMS is pricing Zeposia at the wholesale acquisition cost of $86,000, lower than the tag on Novartis' in-class rival Mayzent.